It s time for the pharmaceutical industry to move in that direction 10

The pharmaceutical industry is a high-tech industry group with a high degree of integration of multidisciplinary advanced technologies and means, involving national health, social stability and economic development. From 1978 to 2008, after 30 years of reform, China's pharmaceutical industry has undergone earth-shaking and rapid changes. Over the past 30 years, China's pharmaceutical industry has been growing faster than gross domestic product (GDP).

From 1978 to 2007, the output value of the pharmaceutical industry increased annually, becoming one of the fastest-growing industries in the national economy.

From January to November 2007, the pharmaceutical manufacturing industry achieved a cumulative total industrial output value of 565,901,53 thousand yuan, a year-on-year increase; The product sales revenue was 520,723,086 thousand yuan, a year-on-year increase; The total realized profit was 49,921,000 yuan. From January to November 2008, the pharmaceutical manufacturing industry achieved a cumulative total industrial output value of 713,658,303 thousand yuan, a year-on-year increase; The product sales revenue was 656,130,000 yuan, a year-on-year increase; The total realized profit was 64,530,215 thousand yuan. In 2008, despite the financial crisis that swept the world, China's pharmaceutical purchase and sales still maintained a steady growth trend, which not only came from the rigid demand for drugs by human beings, but also because China is in the rising channel of improving the medical security system, and the national finance provided strong support for the expansion of the pharmaceutical market.

On January 21, 2009, the executive meeting adopted the "Opinions on Deepening the Reform of the Medical and Health System" and the "Implementation Plan for Deepening the Reform of the Medical and Health System from 2009 to 2011", and a new round of medical reform was officially introduced.

In 2009, with the improvement of the degree of market standardization that may be brought about by the special rectification of the pharmaceutical industry, the market expansion opportunities brought by the new medical reform plan, the increase of new products, the active demand for drug terminals and a new round of investment boom, many favorable factors will ensure the continued rapid growth of China's pharmaceutical industry. However, with the spread of the financial crisis and the deceleration of the world economy, the situation facing China's pharmaceutical foreign trade has become more severe. 2009 is likely to be the most difficult year since the beginning of the new century.

However, due to the characteristics of China's pharmaceutical industry and the role of the new medical reform in stimulating domestic demand, China's total pharmaceutical import and export volume is expected to continue to maintain a certain growth. "Turning pressure into motivation and challenges into opportunities" will become the main theme of China's pharmaceutical foreign trade development in 2009.

Looking forward to the future, the prosperity of China's pharmaceutical industry has just begun, and there is huge room for improvement in the future. The pharmaceutical industry has entered a new round of orderly development under the traction of the new medical reform. By 2010, the increase in drugs brought by medical reform will be at least 100 billion yuan, plus the natural growth of the industry, the annual growth rate of the pharmaceutical industry is expected to be no less than 20% in the next 3-5 years.

China Investment Information Network 2009-2012 China Pharmaceutical Industry Investment Analysis and Prospects** Report.

The pharmaceutical industry is an important part of the national economy, closely related to the vital interests of the people's life, health and quality of life, and is a hot spot of concern for the whole society, as well as an important part of building a harmonious socialist society. At present, China has become one of the world's largest producers and exporters of chemical APIs, and at the same time, it is also the world's largest producer of pharmaceutical preparations. China has become the world's largest producer of vaccine products, and domestic vaccines have begun to provide vaccine products to the World Health Organization for disease prevention in other countries while satisfying the needs of domestic residents for disease prevention and treatment.

Traditional Chinese medicine is an important part of China's pharmaceutical industry, which has received widespread attention from the whole society and widely recognized by all walks of life.

Looking forward to the future of the pharmaceutical industry, the prosperity of China's pharmaceutical industry has just started, and there is huge room for improvement in the future. The pharmaceutical industry has entered a new round of orderly development under the traction of the new medical reform. In the future, the new medical reform plan will have a profound impact on the market structure, industrial structure, product structure and other aspects of China's pharmaceutical industry, coupled with the natural growth of the industry, it is expected that the annual growth rate of the pharmaceutical industry will not be less than 20% in the next 3-5 years.

Prospect of China Pharmaceutical Industry Market Research and Investment Strategic Planning Analysis Report.

China's pharmaceutical market will continue to develop at a high speed:

1. Transformation and innovation. This must be the best path, and innovation must be the general trend in the future, but because the R&D cycle of innovative drugs itself is 5-8 years, it requires the layout of R&D teams, and the expenditure of relatively large R&D investment is not something that can be made this year and next year, so although transformation and innovation is the best track, it takes time.

2. If innovation is difficult for him, he may wish to consider the second path, the development of difficult generic drugs, such as respiratory agents, the product patent has expired, but due to the difficulties in its own dosage form, there may still be some production barriers, this may be the second path, assuming that innovation is not good, you can consider the development of difficult imitation varieties, more typical health yuan and other companies have done very well.

3. If the second is more difficult, the third path is to extend the product line, the listing of a generic drug will face centralized procurement in the short term, and one will not produce 10 or 20 models, and finally there will always be products that can enter the centralized procurement and bring increments, as long as the echelon of the product listing is guaranteed every year, cash flow and profitability can also be achieved in the future, which is also a path, and some companies are also laying out in this area in the current period.

4. For generic drug companies, we summarize that we will consider more about the future impact of centralized procurement on existing pipelines, what is the steady-state situation in the future, and we will consider more about the new pipelines and future development directions in the future, which is the direction we need to pay attention to, and it is the general characteristics and research methods of chemical generics.

On the one hand, we need to pay attention to what the existing products are, whether the field of the big category is a big field, whether the product will be under pressure, what the competition pattern is in the future, and whether it will enter the medical insurance, which is the point we need to pay attention to.

Personally, I believe that the pharmaceutical industry is changing for the better, and the performance of leading companies is stable. Since the beginning of this year, the complexity of the external macro environment has far exceeded market expectations at the beginning of the year, and most areas of the pharmaceutical sector have been relatively less affected by "deleveraging" and rising interest rates, and the certainty of performance trends is relatively high. Since June, the pharmaceutical sector has also adjusted.

We are optimistic about the main logic of the pharmaceutical industry in the medium and long term. First of all, based on domestic demand, domestic demand is upgrading; Secondly, innovation-oriented, innovation is about to rise, and the fundamental direction will not change, but will be strengthened. At present, the track of each sub-industry of the pharmaceutical sector is clear, the head enterprises are relatively clear, and the leading companies are strong.

In the second half of the year, the relative advantages of the high-prosperity sub-sectors of the pharmaceutical sector are still very prominent, the progress of new drug research and development has been verified and the policy continues to advance.

Investment advice: We believe that even if the external environment eases in stages, in the medium and long term, the certainty advantage of the high-boom field of the pharmaceutical sector will still win, and it is recommended that investors stay right and choose stocks from the two main lines. 1. The main line of stock selection based on the subdivision of high prosperity:

1. High-quality prescription drugs (local innovation + high-end imitation): Wuwu Biotechnology, Huadong Medicine, Tonghua Dongbao, Livzon Group, Huahai Pharmaceutical, Changchun High-tech, Nhwa Pharmaceutical, Shanghai Pharmaceutical. 2. Chain pharmacies:

Yixintang, Dashenlin.

People. 3. High-quality medical devices and medical services: Lepu Medical, Antu Biotechnology, Aier Ophthalmology.

Tongce Medical. 2. The main line of stock selection based on changes in market expectations: Shanghai Pharmaceutical, Yunnan Baiyao.

Hualan Biotech.

Analysis of the current pharmaceutical industry in China.